Mecain (Mepivacaine Hydrochloride)

Mepivacaine blocks voltage‑gated sodium channels on neuronal membranes, stopping the influx of sodium ions required for depolarisation. This inhibition prevents the generation and conduction of nerve impulses, resulting in a reversible loss of sensation in the area where the drug is applied.

The appropriate dose of Mecain is determined by the prescribing clinician based on the type of procedure, patient weight, age, and clinical condition. Dosage guidelines are provided in the product label, but the final regimen must be set by a qualified health‑care professional.

Safety data for mepivacaine in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and always under medical advice.

To order Mecain, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Both mepivacaine and lidocaine are amide‑type local anesthetics, but mepivacaine typically has a slightly longer duration of action and a lower pKa, which can result in faster onset. Lidocaine may be preferred for shorter procedures, while mepivacaine is often chosen when a longer block is desired.

Mecain should be stored at room temperature, below 25 °C, in its original sealed container. Protect the solution from direct sunlight, moisture and extreme temperatures. Do not freeze. Inspect the vial for particulate matter before use and discard if the solution appears discoloured.

Mecain is supplied as a sterile solution and is administered by a qualified practitioner via epidural catheter, infiltration injection into soft tissue, or intradermal injection for surface anaesthesia. The route and technique are selected according to the clinical indication and patient needs.

Serious risks include allergic reactions such as anaphylaxis, cardiovascular collapse or severe hypotension, and central nervous system toxicity manifesting as seizures or convulsions. Immediate medical attention is required if any of these events occur during or after administration.

Mecain should be avoided in patients with known hypersensitivity to mepivacaine or other amide‑type local anesthetics, in individuals with severe cardiac conduction disorders, uncontrolled epilepsy, or in those receiving class I antiarrhythmic drugs unless the benefit clearly outweighs the risk.